Welcome to our dedicated page for Celularity SEC filings (Ticker: CELU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Celularity Inc. (NASDAQ: CELU) files a range of documents with the U.S. Securities and Exchange Commission that provide detailed information on its regenerative and aging-related cellular medicine business. These SEC filings include annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements, along with registration statements and other materials related to its capital structure and corporate actions.
For Celularity, periodic reports such as the 10-K and 10-Q describe its focus on advanced biomaterial products and placental-derived cell therapies, outline risk factors, and summarize its financial condition and results of operations. Current reports on Form 8-K disclose material events, including financing arrangements like private placements of Series A Convertible Preferred Stock with accompanying warrants, security agreements, and registration rights agreements, as well as balance sheet restructuring transactions involving the monetization and licensing of intellectual property assets.
Definitive proxy statements, such as the company’s DEF 14A, provide information on matters submitted to stockholders, including the election of directors, ratification of the independent registered public accounting firm, and amendments to equity incentive plans. These documents also discuss Celularity’s capital stock, governance practices, and executive compensation. Together, they offer a structured view of how the company manages its corporate affairs as a Nasdaq-listed issuer.
On this page, Celularity’s SEC filings are presented with real-time updates from EDGAR. Users can access 10-K and 10-Q reports for deeper insight into the company’s regenerative medicine platform and business units, review 8-K filings for recent financing and strategic transactions, and examine proxy materials for governance and equity plan details. AI-powered summaries help explain key terms in complex filings, highlight important provisions in instruments such as preferred stock designations and warrants, and make it easier to understand how specific disclosures may relate to Celularity’s placental-derived products, clinical programs, and financial position.
Celularity Inc. entered a strategic asset purchase and exclusive license agreement with NexGel, Inc. for its commercial-stage biomaterials portfolio and certain development programs. The deal provides up to
Celularity will be the exclusive manufacturer of the licensed products at its FDA-compliant facility, positioning it for ongoing manufacturing revenue and potential royalties on future net sales of certain development-stage products. The company is also realigning its organization, transitioning biomaterials personnel to the partner and further reducing its workforce to lower operating expenses and sharpen its focus on a longevity-focused cell therapy pipeline and scalable manufacturing platform.
Celularity Inc. reported a leadership change in its finance organization. On February 27, 2026, Joseph DosSantos, who was serving as Senior Vice President of Finance and Acting Chief Financial Officer, left the company for personal reasons. On the same date, the company appointed John Sprague as its new Acting Chief Financial Officer. Celularity’s Class A common stock and warrants continue to trade on The Nasdaq Stock Market under the symbols CELU and CELUW.
Celularity Inc. received Amendment No. 1 to a Schedule 13G from Lincoln Alternative Strategies LLC regarding its Class A common stock. The filer now reports beneficial ownership of 0 shares, representing 0% of the class, and indicates ownership of five percent or less of the stock. The certification states the securities were not acquired and are not held to change or influence control of Celularity and are not part of any control-related transaction.
Celularity Inc. reported a change to the employment terms of senior executive John Haines, who serves as Senior Executive Vice President, Global Manager and Chief Administrative Officer. The Compensation Committee approved a first amendment to his amended and restated employment agreement on January 16, 2026. The amendment increases his severance period from 12 months to 24 months, extends company-paid COBRA health coverage to 18 months, and provides that any of his equity options scheduled to vest during the 24 months after a termination will now vest immediately upon his termination. This filing focuses on executive severance protections rather than operating or financial results.
Celularity Inc. director Diane Parks reported receiving 30,000 restricted stock units (RSUs) on January 12, 2026 under the company’s 2021 Equity Incentive Plan. Each RSU represents a right to receive one share of Celularity’s Class A common stock, and this award vests immediately upon grant. After this transaction, she beneficially owns 520,021 shares of Class A common stock in direct ownership.
Celularity Inc. director Peter Diamandis reported an equity award under the company’s 2021 Equity Incentive Plan. On 01/12/2026, he received 20,385 restricted stock units (RSUs), each representing one share of Celularity’s Class A common stock, at a price of $0.00.
The RSUs vest immediately upon grant, meaning they become fully earned right away rather than over time. Following this award, Diamandis beneficially owns 394,150 shares of Class A common stock, all held directly.
Celularity Inc. reported that director Geoffrey Ling received a grant of 19,231 restricted stock units (RSUs) under the company’s 2021 Equity Incentive Plan on January 12, 2026. Each RSU represents one share of Celularity’s Class A common stock, and the RSUs vest immediately upon grant, meaning the shares are no longer subject to a vesting schedule. Following this equity award, Ling now beneficially owns 256,026 shares of Celularity Class A common stock in total, reflecting a routine update to his equity-based director compensation.
Celularity Inc. director Vincent LeVien reported receiving 28,847 restricted stock units (RSUs) of Class A common stock under the company’s 2021 Equity Incentive Plan. Each RSU represents the right to receive one share of Class A common stock, and the filing states that these RSUs vest immediately upon grant as of 01/12/2026. After this equity award, LeVien beneficially owns 153,847 shares of Celularity Class A common stock in total, held directly.
Celularity Inc. director Geoffrey Ling reported receiving 19,231 restricted stock units (RSUs) of Class A common stock. These RSUs were granted under the company’s 2021 Equity Incentive Plan at no cash cost and each unit represents one future share. The RSUs will vest on the earlier of one year from the grant date or the next annual stockholder meeting, as long as he continues serving the company. After this award, Ling beneficially owns 256,026 shares and RSUs in total on a direct basis.
Celularity Inc. director Vincent LeVien reported an award of 28,847 shares of Class A common stock on January 12, 2026, coded as an "A" transaction for an acquisition at a price of $0 per share. These shares are in the form of restricted stock units (RSUs) granted under the Celularity Inc. 2021 Equity Incentive Plan, with each RSU representing the right to receive one share of Class A common stock.
The RSUs will vest and become exercisable on the earlier of the one-year anniversary of the grant date and the next annual stockholder meeting, as long as LeVien continues to provide service to the company through that date. Following this grant, he beneficially owns a total of 153,847 shares of Class A common stock in direct ownership.